Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBK | Q96KB5 | 4/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.43 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2749580 | 0.84 | KDM5A (0.50) | PBKCYP3A4ALDH1A1CYP3A5CAMKK2 | |
| SCHEMBL18225726 | 0.82 | PBK (0.44) | PBKMKNK1CYP3A4ALDH1A1CYP3A5 | |
| SCHEMBL2005974 | 0.82 | PBK (0.48) | PBKCYP3A4ALDH1A1CYP3A5CAMKK2 | |
| SCHEMBL18248944 | 0.79 | PBK (0.42) | PBKMKNK1CYP3A4ALDH1A1CYP3A5 | |
| SCHEMBL18248945 | 0.79 | PBK (0.42) | PBKMKNK1CYP3A4ALDH1A1CYP3A5 | |
| SCHEMBL18225106 | 0.78 | PBK (0.50) | PBKMKNK1CYP3A4ALDH1A1CYP3A5 | |
| SCHEMBL18248911 | 0.78 | PBK (0.41) | PBKCYP3A4ALDH1A1CYP3A5LRRK2 | |
| SCHEMBL18225384 | 0.73 | CYP3A4 (0.61) | PBKCYP3A4CYP3A5AURKABRD4 | |
| SCHEMBL18248915 | 0.71 | EGFR (0.47) | PBKCYP3A4ALDH1A1CYP3A5CSF1R | |
| SCHEMBL18224844 | 0.71 | CYP3A4 (0.64) | PBKCYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011002772-A1 | IMIDAZOPYRIDINE DERIVATIVES AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-01-06 | — | — | WO | claimed |
| EP-3294732-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Gilead Sciences, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016186967-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20100234593-A1 | Imidazo[4,5-B]Pyridine-7-Carboxamides 704 | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | disclosed |
| CN-101679421-A | Novel imidazo [4, 5-b ] pyridine-7-carboxamides 704 | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234593-A1 | Imidazo[4,5-B]Pyridine-7-Carboxamides 704 | HDAC4, HDAC7, BRD4 | PBK 1618/4885MKNK1 3343/4885CYP3A4 13/4885 |
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | PBK 4051/4885MKNK1 1522/4885CYP3A4 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.